91 related articles for article (PubMed ID: 29126568)
21. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
22. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
23. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
24. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK
World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643
[TBL] [Abstract][Full Text] [Related]
25. Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.
Ederer IA; Lucca I; Hofbauer SL; Haidinger M; Haitel A; Susani M; Shariat SF; Klatte T
World J Urol; 2015 Dec; 33(12):2087-93. PubMed ID: 25860378
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
[TBL] [Abstract][Full Text] [Related]
27. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
[TBL] [Abstract][Full Text] [Related]
29. De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
Palazzetti A; Bosio A; Dalmasso E; Destefanis P; Fop F; Pisano F; Segoloni G; Biancone L; Volpe A; Di Domenico A; Terrone C; Iesari S; Famulari A; Todeschini P; Frea B; Gontero P
Urol Int; 2018; 100(2):185-192. PubMed ID: 29342465
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
31. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?
Thomas F; Rosario DJ; Rubin N; Goepel JR; Abbod MF; Catto JW
Cancer; 2012 Nov; 118(22):5525-34. PubMed ID: 22544645
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
33. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
34. Nephrogenic adenoma of the bladder in renal transplant and non-renal transplant patients: a review of 22 cases.
Tse V; Khadra M; Eisinger D; Mitterdorfer A; Boulas J; Rogers J
Urology; 1997 Nov; 50(5):690-6. PubMed ID: 9372876
[TBL] [Abstract][Full Text] [Related]
35. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Lykke MR; Nielsen TK; Ebbensgaard NA; Zieger K
Scand J Urol; 2015 Jun; 49(3):230-6. PubMed ID: 25731785
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
37. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.
Rodríguez Faba O; Palou J
Curr Opin Urol; 2012 Sep; 22(5):415-20. PubMed ID: 22825460
[TBL] [Abstract][Full Text] [Related]
39. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?
Kiss B; Schneider S; Thalmann GN; Roth B
Int J Urol; 2015 Feb; 22(2):158-62. PubMed ID: 25339291
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
